Bellevue Group Ag Clovis Oncology, Inc. Transaction History

Bellevue Group Ag

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 13, 2020	SELL	$5.69 - $9.69 $405,128 - $689,928	-71,200 Closed	0 $0
Q1 2020 May 14, 2020	SELL	$3.77 - $11.0 $6,409 - $18,700	-1,700 Reduced 2.33%	71,200 $453,000
Q4 2019 Feb 14, 2020	BUY	$3.0 - $16.43 $218,700 - $1.2 Million	72,900 New	72,900 $760,000
Q3 2018 Nov 13, 2018	SELL	$29.37 - $49.48 $506,632 - $853,530	-17,250 Closed	0 $0
Q2 2018 Aug 07, 2018	SELL	$42.06 - $62.4 $21,030 - $31,200	-500 Reduced 2.82%	17,250 $784,000
Q1 2018 May 09, 2018	SELL	$50.12 - $67.72 $12,530 - $16,930	-250 Reduced 1.39%	17,750 $937,000
Q4 2017 Feb 14, 2018	SELL	$57.69 - $84.58 $28,845 - $42,290	-500 Reduced 2.7%	18,000 $1.22 Million
Q2 2017 Aug 14, 2017	BUY	N/A	18,500	18,500 $1.73 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

Stay updated on Bellevue Group Ag with notifications on news.